$Brainstorm Cell Therapeutics (BCLI.US)$BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS Meeting 5 MINUTES AGO, 6:00 AM EDT VIA PR NEWSWIRE Biomarker data suggest ALS patients may benefit from longer-term treatment with NurOwn Poster highlighting design of planned Phase 3b NurOwn trial also presented
Brainstorm Cell Therapeutics股票討論
PR Newswire· 3分鐘前
已簽署諒解備忘錄
紐約,2024年11月11日/ PRNewswire/ - BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI),一家致力於治療神經退行性疾病的細胞治療領先開發商,今天宣佈已與Pluri Inc. (NASDAQ: PLUR) 簽署諒解備忘錄(MOU)。
28/10/2024 - 18:00
生物標記數據顯示ALS患者可能從較長期的NurOwn治療中受益
海報也展示了計劃中的第30億NurOwn試驗的設計
2024年10月28日,紐約/美通社訊—brainstorm cell therapeutics公司(納斯達克:BCLI),一家領先的神經退行性疾病細胞療法開發商...
5 MINUTES AGO, 6:00 AM EDT
VIA PR NEWSWIRE
Biomarker data suggest ALS patients may benefit from longer-term treatment with NurOwn
Poster highlighting design of planned Phase 3b NurOwn trial also presented
暫無評論